Why it Works
About Inosine Pranobex
Inosine pranobex has been approved in >70 countries for treatment of various viral infections with continued positive benefit vs. risk profile over last 50 years. Its legal re-classification from POM to OTC category in some countries further reiterates its efficacy & safety, indicating it as a “Well Established Medicine”.
Human PK, PD and clinical efficacy and safety has been established in numerous clinical trials in different indications, dose ranges, and in different patient population.
Inosine pranobex acts by strengthening body’s immune response to viral infections, and also inhibits viral replication by slowing down viral mRNA synthesis.
Data from various studies in more than 800 COVID-19 patients confirm that it produced earlier clinical improvement and cure in significantly higher number of patients when added to the standard of care in patients with mild to moderate COVID-19, and reduced case fatality rate in elderly patients.
Soon to be introduced in India as a ‘Prescription Only Medicine (POM)’ as Viralex® 500mg tablets.
Due to the frequently mutating trend of the virus, the uncertainties of the pandemic continue. Viralex® is a new ray of hope in these challenging times. It enhances host immunity and continues to provide its beneficial effect to fight viral infections. It is an effective medicine with an established safety profile and will offer a much-needed therapeutic solution to address the unmet need in the management of COVID-19.
About the Parent Organisation
50 years of excellence in Pain Management and Critical Care
Themis is a research-based pharmaceutical company specializing in manufacture of a wide range of products for application areas like Pain Management, Critical Care and Anti-Infectives. We develop high response differentiated products through our platform technologies with a clear focus on patient benefit.
Our vision is to develop medicines that benefit patients and make healthcare far, far more effective.